Related Experiment Video
Updated: Jul 20, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro
H Mohseni1, S Zaslau, D McFadden
1Department of Surgery, Robert C. Byrd Health Science Center, West Virginia University, Morgantown, West Virginia 26506, USA.
Purpose:
The purpose of this work was to determine the in vitro effect of Rofecoxib and specific COX 1 and COX 2 inhibitors in regards to cell growth and apoptotic and necrotic activity.
Introduction And Objective:
Rofecoxib (Vioxx) is a nonsteroidal anti-inflammatory agent (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). The inducible isoform of COX-2 is overexpressed in many gastrointestinal and genitourinary tract tumors. We hypothesized that in vitro treatment with both COX-1 and COX-2 inhibitors would significantly reduce cellular proliferation of bladder cancer cells by apoptotic pathways.
Materials And Methods:
Two human bladder cancer cell lines were grown in culture using standard techniques and treated with Rofecoxib at doses ranging from 125 microg/well serially diluted down to 8.0 microg/well. Catechin (COX 1 inhibitor) and NS398 (COX 2 inhibitor) were used at doses of 50 and 100 microM. Cell viability was measured by MTT at 24 and 72 h. Apoptosis was evaluated by the Annexin V FITC Assay. Statistical analysis was performed by ANOVA.
Results:
Rofecoxib, Catechin, and NS398 all exhibited significant inhibition of cell growth when compared to the nontreated controls. Significant changes in apoptotic activity were observed in all agents tested in both the T24 and the TCCSUP cells.
Conclusions:
Selective COX-2 inhibition, using the well-tolerated and commercially available Rofecoxib (VIOXX) and specific COX 1 and 2 inhibitors, reduced the growth of human bladder cancer in vitro by apoptotic mechanisms. Further in vivo and human studies are warranted to evaluate the safety and clinical utility of this agent in patients with bladder cancer.
Insights
Rofecoxib and other COX inhibitors significantly reduced bladder cancer cell growth in vitro by inducing apoptosis. Further studies are needed to explore Rofecoxib
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) is overexpressed in various tumors, including bladder cancer.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like Rofecoxib selectively inhibit COX-2.
- Targeting COX pathways presents a potential therapeutic strategy for cancer treatment.
Purpose of the Study:
- To investigate the in vitro effects of Rofecoxib and specific COX-1/COX-2 inhibitors on bladder cancer cell growth.
- To determine the impact of these inhibitors on apoptotic and necrotic activity in bladder cancer cells.
- To test the hypothesis that COX inhibitors reduce bladder cancer cell proliferation via apoptosis.
Main Methods:
- Two human bladder cancer cell lines (T24 and TCCSUP) were cultured.
- Cells were treated with Rofecoxib, Catechin (COX-1 inhibitor), and NS398 (COX-2 inhibitor) at varying concentrations.
- Cell viability was assessed using MTT assays, and apoptosis was evaluated via Annexin V FITC staining.
Main Results:
- Rofecoxib, Catechin, and NS398 demonstrated significant inhibition of bladder cancer cell growth compared to controls.
- All tested agents induced significant changes in apoptotic activity in both T24 and TCCSUP cell lines.
- No significant differences in necrotic activity were explicitly mentioned in the abstract.
Conclusions:
- Selective COX-2 inhibition with Rofecoxib and other COX inhibitors effectively reduced in vitro growth of human bladder cancer cells.
- The observed growth inhibition was mediated through apoptotic mechanisms.
- Further in vivo and clinical studies are recommended to assess the safety and efficacy of Rofecoxib for bladder cancer treatment.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019